Hansa Biopharma AB (OSTO:HNSA)
kr 42.46 0.62 (1.48%) Market Cap: 2.78 Bil Enterprise Value: 3.18 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 73/100

Hansa Biopharma AB Deep Dive: Gene Therapy Hosted by HC Andersen Capital Transcript

Nov 05, 2021 / 10:00AM GMT
Release Date Price: kr95.48 (-1.53%)
Henrik Ekman

Yes. Welcome to this digital event with Hansa Biopharma. My name is Henrik Ekman. I'm equity analyst at the HC Andersen Capital. And it's a pleasure for me to introduce Lena Winstedt from Hansa Biopharma, who will take us through a presentation of the gene therapy area within Hansa. The primary focus is to get a better basic understanding for the area. And as always, the format is that we will have a presentation, and then there will be opportunity to ask questions afterwards, which you are welcome to -- the audience is welcome to put forward in the chat, and I will do my best to try and forward the question to Lena when she's done her presentation.

So with that, Lena, a very warm welcome to you. And we are very excited to hear of this part of Hansa, which we are not used to hear about so much. So please take us through your presentation of the gene therapy area.

Lena Winstedt;publ;Head of Science
Hansa Biopharma AB

()-

Thank you. I just want to show you or tell you that this presentation will contain some forward

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot